Y-mAbs Therapeutics, Inc. YMAB

Set alert

Price alert · YMAB

All alert types
8.61 0.00 0.00%

At close · Sep 16

8.61 Day range 8.61
8.59 52-week range 8.61
Open
8.61
Prev close
8.61
Mkt cap
391.22M
Vol
760.67K
Avg vol
676.58K
EPS
-0.50
P/E
0.00
Div yield
0.00%
More statistics
Low
8.61
High
8.61
Forward P/E
-13.98
Beta
0.67
Short ratio
13.91
Inst. own
72.19%
Dividend
0.00
Ex-div date
Earnings
Aug 12, 2024
50-d avg
12.41
200-d avg
13.15
1y target
20.64

6M chart

Chart tools
Interval

Signals (33)
NameDateAgo
MACD: Sell SignalAug 25, 20251 year ago
SMA: BullishAug 5, 20251 year ago
SMA: BullishAug 5, 20251 year ago
MACD: Buy SignalAug 5, 20251 year ago
RSI: OverboughtAug 5, 20251 year ago
MACD: Sell SignalAug 4, 20251 year ago
SMA: BearishJul 31, 20251 year ago
SMA: BearishJul 31, 20251 year ago
SMA: BullishJul 23, 20251 year ago
SMA: BullishJul 23, 20251 year ago
MACD: Buy SignalJul 23, 20251 year ago
SMA: BearishJul 11, 20251 year ago
SMA: BullishJul 10, 20251 year ago
SMA: BearishJul 1, 20251 year ago
SMA: BearishJun 26, 20251 year ago
SMA: BullishJun 24, 20251 year ago
SMA: BullishJun 23, 20251 year ago
SMA: BearishJun 20, 20251 year ago
MACD: Sell SignalJun 17, 20251 year ago
SMA: BearishJun 11, 20251 year ago

Newest 20 of 33.

Analyst view

Consensus: buy

Buy
Price target (mean) 20.64 +139.7% upside
Target (low)
11.00
Target (mean)
20.64
Target (high)
26.00
Ratings (0m) 11 9 buy · 1 hold · 1 sell
  • Strong buy2
  • Buy7
  • Hold1
  • Sell1
  • Strong sell0

Recommendation trend

  • This month 11
  • 1 month ago 10
  • 2 months ago 9
  • 3 months ago 9

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

YMAB analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.1225-0.25 – 0.05-0.02-512.5%26.99M+15.5%10
Next quarter-0.14667-0.22 – -0.04-0.15+2.2%24.37M+22.3%5
Current year-0.57625-0.83 – -0.21-0.49-17.6%88.53M+4.4%10
Next year-0.46875-0.95 – -0.15-0.57625+18.7%106.84M+20.7%10

Upgrades and downgrades

The latest rating changes

YMAB analyst upgrades and downgrades
DateFirmActionFromTo
Dec 11, 2024HC Wainwright & Co.ReiteratedBuyBuy
Dec 5, 2024Brookline CapitalInitiated—Buy
Nov 18, 2024OppenheimerInitiated—Outperform
Nov 15, 2024HC Wainwright & Co.ReiteratedBuyBuy
Sep 10, 2024WedbushReiteratedOutperformOutperform
Sep 9, 2024Cantor FitzgeraldReiteratedOverweightOverweight
Aug 16, 2024Cantor FitzgeraldInitiated—Overweight
Aug 13, 2024Canaccord GenuityMaintainedBuyBuy
Aug 13, 2024Morgan StanleyMaintainedUnderweightUnderweight
Aug 13, 2024HC Wainwright & Co.ReiteratedBuyBuy
Aug 13, 2024BMO CapitalMaintainedOutperformOutperform
Jul 11, 2024Jones TradingInitiated—Buy
Jun 28, 2024Truist SecuritiesInitiated—Buy
May 13, 2024HC Wainwright & Co.MaintainedBuyBuy
Mar 6, 2024HC Wainwright & Co.MaintainedBuyBuy
Mar 4, 2024Canaccord GenuityMaintainedBuyBuy
Mar 4, 2024BMO CapitalMaintainedOutperformOutperform
Feb 20, 2024HC Wainwright & Co.MaintainedBuyBuy
Nov 15, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 22, 2023JP MorganMaintainedUnderweightUnderweight
Aug 14, 2023Morgan StanleyMaintainedUnderweightUnderweight
Aug 14, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jul 25, 2023Canaccord GenuityMaintainedBuyBuy
Jun 7, 2023Canaccord GenuityReiteratedBuyBuy
May 15, 2023B of A SecuritiesMaintainedNeutralNeutral
May 10, 2023Morgan StanleyMaintained—Underweight
May 10, 2023WedbushUpgradeNeutralOutperform
May 9, 2023Canaccord GenuityMaintained—Buy
Apr 4, 2023HC Wainwright & Co.Maintained—Buy
Apr 3, 2023GuggenheimDowngradeBuyNeutral